Diagnosis of liver fibrosis: an emphasis on elastography

In the strategy of managing patients with chronic diffuse liver diseases, the priority areas are the determination of the diagnosis with the determination of the main risk factors, the activity of the process (steatosis, steatohepatitis), as well as the degree of fibrous transformation. The rate of progression of liver fibrosis is a decisive factor that will determine the prognosis, treatment tactics and the likelihood of severe complications. The “gold standard” for diagnosing chronic liver pathology is a puncture liver biopsy with morphological examination of the liver tissue. At the same time, potential complications, contraindications to the procedure, low patient compliance, as well as errors in the interpretation of the results obtained due to various reasons are significant limitations of this diagnostic method. These shortcomings were the reason for the search for reliable non-invasive methods for diagnosing liver fibrosis both during the initial examination and during subsequent monitoring in dynamics. Modern methods of liver elastography are widely used for non-invasive assessment of fibrosis, demonstrating good diagnostic capabilities and significantly reducing the need for liver biopsy. Various elastography methods, which have their own advantages and disadvantages, effectively complement each other, which is successfully used in clinical practice in the diagnosis of fibrous transformation. The combined use of elastographic methods and commercial predictive diagnostic panels will increase the diagnostic accuracy in the determination of liver fibrosis.

1. Zhirkov I.I., Gordienko A. V., Yakovlev V. V., et al. Possibilities of transient and two-dimensional shear wave elastography in the diagnosis of fibrosis in nonviral chronic diffuse liver diseases in military personnel. Bulletin of the Russian Military Medical Academy. 2020; 22(2):11-15. (in Russ.) doi: 10.17816/brmma50037.

2. Shirokikh I.N., Mavlitova L. A., Tuev A. V., Khlynova O. V. liver fibrosis diagnosis: are the methods perfect? Perm Medical Journal. 2013;30(3):93-102. (in Russ.) doi: 10.17816/pmj30393-102.

3. Balukova E.V., Uspenskiy Yu.P., Fominykh Yu. A. Liver diseases of various genesis (toxic, drug-induced, dysmetabolic): from etiological heterogenicity to a single unified therapy of patients. RMJ. Medical Review. 2018. no 1(I), pp. 35-40. (In Russ.)

4. Krolevets T.S., Livzan M. A., Chebanenko E. V., et al. Predictive model of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty liver disease. Sovremennyye problemy nauki i obrazovaniya, 2018, no. 3, pp. 74-85. (In Russ.)

5. Zhirkov I.I., Gordienko A. V., Pavlovich I. M., Yakovlev V. V., et al. Possibilities of transient and two-dimensional shear wave elastography in the diagnosis of fibrosis in chronic diffuse liver diseases of non-viral etiology. Experimental and Clinical Gastroenterology. 2020;(7):86-91. (In Russ.) doi: 10.31146/1682-8658-ecg-179-7-86-91.

6. Izranov V.A., Kazantseva N. V., Martinovich M. V., et al. Methods of liver elastography and problems of Russian-language terminology. IKBFU's Vestnik, 2019, no. 1, pp. 63-78. (In Russ.)

7. Izranov V.A., Kazantseva N. V., Martinovich M. V., et al. Physical basis of liver elastography. IKBFU's Vestnik, 2019, no. 2, pp. 69-87. (In Russ.)

8. Angulo P., Hui J. M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, Vol. 45, pp. 846-854. doi: 10.1002/hep.21496.

9. Hagstrom Н., Nasr P., Ekstedt M., et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 2017;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027.

10. Zhirkov I.I., Gordienko A. V., Serdyukov D. Yu., et al. Diagnostic strategy for non-alcoholic fatty liver disease. Bulletin of the Russian Military Medical Academy, 2019; 67(3): 195-200. (In Russ.)

11. Ivashkin V.T., Mayevskaya M. V., Zharkova M. S. et al. Diagnostic and treatment algorithms in hepatology: reference materials. Moscow: MEDpress-inform, 2016, pp. 43-54. (In Russ.)

12. Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S., et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientifi c Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2016; 26(1): 24-42. (In Russ.)

13. Lazebnik L.B., Radchenko V. G., Golovanova E. V. et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (Recommendations for therapists, 2nd edition). Experimental and Clinical Gastroenterology, 2017, no. 2, pp. 22-37. (In Russ.)

14. Isakov V. A. How to determine the severity of liver fibrosis and why? Clinical Gastroenterology and Hepatology. 2008, no. 2, pp. 72-75. (In Russ.)

15. Sporea I., Popescu A., Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J. Gastroenterol, 2008, Vol. 21, pp. 3396-3402. doi: 10.3748/wjg.14.3396.

16. Szymczak A., Simon K., Inglot M., Gladysz A. Safety and effectiveness of blind percutane ous liver biopsy: analysis of 1412 procedures. Hepat Mon, 2012;12(1): 32-37. doi: 10.5812/kowsar.1735143x.4388.

17. Regev A., Berho M., Jeffers L. J., et al. Sampling error and in traobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol, 2002; 97(10):2614-2618. doi: 10.1111/j.1572-0241.2002.06038.x.

18. Arun J., Jhala N., Lazenby A. J., et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes. Surg, 2007;17(2):155-161. doi: 10.1007/s11695-007-9041-2.

19. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology, 2003; 38(6):1449-1457. doi: 10.1016/j.hep.2003.09.022.

20. Borsukov A.V., Venidiktova D. Yu. Assessment of the comparative effectiveness of methods for instrumental diagnosis of liver steatosis in patients with metabolic syndrome. Practical Medicine, 2018;113(2):16-21. (In Russ.)

21. Zhirkov I.I., Gordienko A. V., Pavlovich I. M., et al. Elastography in the diagnosis of fibrosis in chronic diffuse liver diseases. Bulletin of the Russian Military Medical Academy. 2020;72(4):192-195. (In Russ.)

22. Ophir J., Cespedes I., Ponnekanti H., et al. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging, 1991, Vol. 13, pp. 111-134. doi: 10.1177/016173469101300201.

23. Zhirkov I.I., Gordienko A. V. Elastography in the diagnosis of chronic non-viral diffuse liver diseases: (Guidelines). Moscow: New format, 2021, 90 p. (In Russ.)

24. Shiina Т. JSUM ultrasound elastography practice guidelines: basics and terminology. Journal of Medical Ultrasonics, 2013;40(4):325-357. doi: 10.1007/s10396-013-0490-z.

25. Zykin B.I., Postnova N. A., Medvedev M. E. [Elastography: anatomy of the method]. Promeneva diahnostyka, promeneva terapiya = Radiation diagnostics, radiation therapy, 2012, no. 2-3, pp. 107-113. (In Russ.)

26. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996;24(2): 289293. doi: 10.1002/hep.510240201.

27. Mitkov V.V., Mitkova M. D. Shear wave ultrasound elastography. Ultrasound and Functional Diag nostics. 2015, no. 2, pp. 94-108. (In Russ.)

28. Dietrich C.F., Barr R. G., Farrokh A., et al. Strain elastography - how to do it? Ultrasound International Open, 2017;3 (4): 137-149. doi: 10.1055/s-0043-119412.

29. Dietrich C.F., Bamber J., Berzigotti A., et al. EFSUMB Guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). European Federation for Ultrasound in Medicine and Biology (EFSUMB). Ultraschall in der Medizin, 2017;38(4): 16-47. doi: 10.1055/s-0043-103952.

30. Fujimoto K., Tatsumi C., Ueshima K. et al. Evaluation of liver fibrosis in diffuse liver disease using realtime tissue elastography. Digestive Disease Week, May 30th - June 4th, 2009. Chicago, USA. p. 1774. doi: 10.1016/S0016-5085(09)63848-8.

31. Tatsumi C., Kudo M., Ueshima K. Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. Intervirology, 2008, no. 51, pp. 27-33. doi: 10.1159/000122602.

32. Postnova N.A., Borsukov A. V., Morozova T. G. et al. Th e use of compression elastography for non-invasive assessment of liver fibrosis: results of a multicenter study. Ultrasound and Functional Diagnostics, 2016, no. 6, pp. 10-21. (In Russ.)

33. Morozova T.G., Borsukov A. V. Advanced features of elastographic research methods on the example of their complex use. Practical medicine, 2016;101(9):69-73. (In Russ.)

34. Venkatesh S.K., Yin M., Ehman R. L. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. Journal of Magnetic Resonance, 2013, Vol. 37, pp. 544-555. doi: 10.1002/jmri.23731.

35. Mariappan Y.K., Glaser K. J., Ehman R. L. Magnetic resonance elastography: a review. Clinical Anatomy, 2010;(23): 497-511. doi: 10.1002/ca.21006.

36. Venkatesh S.K., Yin M., Ehman R. L. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. Journal of Magnetic Resonance, 2013, Vol. 37, pp. 544-555. doi: 10.1002/jmri.23731.

37. Dulai P.S., Sirlin C. B., Loomba R. Magnetic resonance imaging and magnetic resonance elastography for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. Journal of Hepatology, 2016, Vol. 65, pp. 1006-1016. doi: 10.1016/j.jhep.2016.06.005.